Etanercept - TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers?

被引：46

作者：

Marotte, Hubert ^{[1
]}

Cimaz, Rolando ^{[2
]}

机构：

[1] CHU St Etienne, Hop Nord, Dept Rheumatol, St Etienne, France

[2] Univ Florence, Anna Meyer Childrens Hosp, Dept Pediat, Rheumatol Unit, Florence, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2014年 / 14卷 / 05期

关键词：

efficacy; etanercept; side effect; TNF blockers; RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; ALPHA AGENTS; NECROSIS; THERAPY; TUBERCULOSIS; INFLIXIMAB; UVEITIS; RISK; ANTAGONISTS;

D O I：

10.1517/14712598.2014.896334

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

TNF blockers have been available to treat various inflammatory disorders since more than a decade. T cells and macrophages mainly express TNF and activate many cells through two types of receptors. Pharmaceutical companies developed two types of TNF blockers: soluble receptors and monoclonal antibodies. Understanding of differences of structure and function can explain divergence of efficacy or side effects. Etanercept has the best retention rate in rheumatic diseases, but is less or not effective in granulomatous diseases, such as inflammatory bowel diseases or uveitis. However, etanercept induces less tuberculosis infections than anti-TNF blocker monoclonal antibodies.

引用

页码：569 / 572

页数：4

共 24 条

[1]

Adalimumab in the therapy of uveitis in childhood [J].

Biester, Sabine ;

Deuter, Christoph ;

Michels, Hartmut ;

Haefner, Renate ;

Kuemmerle-Deschner, Jasmin ;

Doycheva, Deshka ;

Zierhut, Manfred .

BRITISH JOURNAL OF OPHTHALMOLOGY, 2007, 91 (03) :319-324

[2]

Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases [J].

Daien, Claire Immediato ;

Monnier, Agnes ;

Claudepierre, Pascal ;

Constantin, Arnaud ;

Eschard, Jean-Paul ;

Houvenagel, Eric ;

Samimi, Mahtab ;

Pavy, Stephan ;

Pertuiset, Edouard ;

Toussirot, Eric ;

Combe, Bernard ;

Morel, Jacques .

RHEUMATOLOGY, 2009, 48 (08) :883-886

[3]

mTNF reverse signalling induced by TNFα antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease [J].

Derer, Stefanie ;

Till, Andreas ;

Haesler, Robert ;

Sina, Christian ;

Grabe, Nils ;

Jung, Sascha ;

Nikolaus, Susanna ;

Kuehbacher, Tanja ;

Groetzinger, Joachim ;

Rose-John, Stefan ;

Rosenstiel, Philip C. ;

Schreiber, Stefan .

GUT, 2013, 62 (03) :376-386

[4]

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) [J].

Dixon, W. G. ;

Hyrich, K. L. ;

Watson, K. D. ;

Lunt, M. ;

Galloway, J. ;

Ustianowski, A. ;

Symmons, D. P. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (03) :522-528

[5]

Furst DE, 2005, J RHEUMATOL, V32, P2303

[6]

Furst DE, 2003, J RHEUMATOL, V30, P2123

[7]

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [J].

Hanauer, SB ;

Feagan, BG ;

Lichtenstein, GR ;

Mayer, LF ;

Schreiber, S ;

Colombel, JF ;

Rachmilewitz, D ;

Wolf, DC ;

Olson, A ;

Bao, WH ;

Rutgeerts, P .

LANCET, 2002, 359 (9317) :1541-1549

[8]

Certolizumab pegol for the treatment of rheumatoid arthritis [J].

Horton, Sarah ;

Walsh, Ceara ;

Emery, Paul .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (02) :235-249

[9]

Joyau C, 2012, CLIN EXP RHEUMATOL, V30, P700

[10]

Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent [J].

Keane, J ;

Gershon, S ;

Wise, RP ;

Mirabile-Levens, E ;

Kasznica, J ;

Schwieterman, WD ;

Siegel, JN ;

Braun, MM .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (15) :1098-1104

← 1 2 3 →